Lipocine Inc. Files 8-K for Other Events and Exhibits

Ticker: LPCN · Form: 8-K · Filed: 2024-09-30T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, SEC filing, financial-reporting

TL;DR

Lipocine filed a routine 8-K on 9/30/24 for other events and exhibits.

AI Summary

Lipocine Inc. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing does not detail specific transactions or material events, but serves as a routine update and filing of exhibits.

Why It Matters

This 8-K filing indicates Lipocine Inc. is providing updates and submitting necessary financial documents to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This filing appears to be a routine administrative filing with no immediately apparent material adverse information.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?

The provided text does not specify the details of the 'Other Events' beyond listing it as an item information category.

When was the earliest event reported in this Form 8-K?

The earliest event reported was on September 30, 2024.

What is Lipocine Inc.'s state of incorporation?

Lipocine Inc. is incorporated in Delaware.

What is the principal executive office address for Lipocine Inc.?

The principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the SEC file number for Lipocine Inc.?

The SEC file number for Lipocine Inc. is 001-36357.

From the Filing

0001493152-24-038728.txt : 20240930 0001493152-24-038728.hdr.sgml : 20240930 20240930093522 ACCESSION NUMBER: 0001493152-24-038728 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240930 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240930 DATE AS OF CHANGE: 20240930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241337056 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-09-30 2024-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): September 30, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company issued a press release announcing that it will present and meet with investors at the H.C. Wainwright 8 th Annual MASH Investor Conference, to take place virtually on October 7, 2024. The press release is filed as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description       99.1   Press Release announcing Lipocine to Present at the H.C. Wainwright 8 th Annual

View on Read The Filing